diff --git a/content/acetate.html b/content/acetate.html index 22b80d99a1f6806e8b822950560a3d9d2ba04072..73f72c6fe816a2f0d8f1fab5cbe18f7c46d00f32 100644 --- a/content/acetate.html +++ b/content/acetate.html @@ -36,7 +36,7 @@ monocarboxylate transporter and <a href="./target_aquaporins.html">aquaporins</a across cell membranes.</p> <p><a href="./pic/acetate-acetylCoA.svg"><img src="./pic/acetate-acetylCoA.svg" - alt="acetate to acetyl-CoA conversion by ACH" + alt="acetate to acetyl-CoA conversion by ACH" title="acetate to acetyl-CoA conversion by ACH" style="padding:6px 0px 0px 6px; width:350px; float:right;" /></a> </p> @@ -74,9 +74,9 @@ acetate (<a href="https://doi.org/10.1016/0969-8051(94)90178-3">Kihlberg et al., <div class="images"> <a href="./pic/1-11C-acetate.svg"><img src="./pic/1-11C-acetate.svg" height="80" - alt="[1-11C]Acetate" style="padding:0px 10px 0px 0px;" /></a> + alt="[1-11C]Acetate" title="[1-11C]Acetate" style="padding:0px 10px 0px 0px;" /></a> <a href="./pic/2-11C-acetate.svg"><img src="./pic/2-11C-acetate.svg" height="80" - alt="[2-11C]Acetate" style="padding:0px 10px 0px 0px;" /></a> + alt="[2-11C]Acetate" title="[2-11C]Acetate" style="padding:0px 10px 0px 0px;" /></a> <p>[1-<sup>11</sup>C]Acetate and [2-<sup>11</sup>C]acetate, labelled into C-1 and C-2 position, respectively.</p> </div> @@ -116,7 +116,8 @@ of astrocytic metabolism in the brain <h2><a name="18F"><sup>18</sup>F-labelled acetate</a></h2> <p><a href="./pic/18F-fluoroacetate.svg"><img src="./pic/18F-fluoroacetate.svg" - alt="18F-fluoroacetate" style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a> + alt="18F-fluoroacetate" title="18F-fluoroacetate" + style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a> </p> <p>The hydrogen atoms of the methyl group can be replaced with <sup>18</sup>F to produce @@ -163,22 +164,6 @@ it with ethanol to increase lipophilicity. The resulting proradiotracer [<sup>18 the brain rapidly and was converted to TCA cycle metabolites (<a href="https://doi.org/10.1016/j.nucmedbio.2008.11.006">Mori et al., 2009</a>).</p> -<!-- Moved into its own page - -<p><a href="./pic/2-18F-fluoropropionate.svg"><img src="./pic/2-18F-fluoropropionate.svg" - alt="18F-labelled propionate" style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a> -</p> - -<h3><a name="FPA">2-[<sup>18</sup>F]fluoropropionate</a></h3> - -<p>2-[<sup>18</sup>F]fluoropropionate is another SCFA radiopharmaceutical that mimics acetate, -and could be used in tumour imaging because of increased fatty acid synthesis -(<a href="https://doi.org/10.2967/jnumed.109.064212">Pillarsetty et al., 2009</a>; -<a href="https://doi.org/10.1177/1536012118821032">Zhao et al., 2019</a>; -Zhang et al., <a href="https://doi.org/10.1007/s11307-019-01346-1">2019</a> and -<a href="https://doi.org/10.1007/s11307-021-01608-x">2021</a>).</p> ---> - <br> <h2>See also:</h2> diff --git a/content/analysis_11c-pbr28.html b/content/analysis_11c-pbr28.html index f05e5d6daf67184ed759032b92f778baf8a9fac9..149b4b94c4519dd280de11da2f12622bfc85a537 100644 --- a/content/analysis_11c-pbr28.html +++ b/content/analysis_11c-pbr28.html @@ -12,7 +12,7 @@ tags: <h1>Quantification of [<sup>11</sup>C]PBR28 PET studies</h1> -<p><a href="./pic/11C-PBR28.svg"><img src="./pic/11C-PBR28.svg" alt="11C-PBR28" +<p><a href="./pic/11C-PBR28.svg"><img src="./pic/11C-PBR28.svg" alt="11C-PBR28" title="11C-PBR28" style="padding:10px 0px 0px 10px; width:150px; float:right;" /></a> </p> diff --git a/content/analysis_11c-pib.html b/content/analysis_11c-pib.html index fe78b3f402f890fc0a38b956e7f6525ea4ff1a51..fe13d387b6a144460ef4538cd4e2201499629a60 100644 --- a/content/analysis_11c-pib.html +++ b/content/analysis_11c-pib.html @@ -13,7 +13,7 @@ tags: <h1>Analysis of [<sup>11</sup>C]PIB PET data</h1> <div> -<p><a href="./pic/11C-PIB.svg"><img src="./pic/11C-PIB.svg" alt="11C-PIB" +<p><a href="./pic/11C-PIB.svg"><img src="./pic/11C-PIB.svg" alt="11C-PIB" title="11C-PIB" style="padding:10px 0px 0px 10px; width:200px; float:right;" /></a> </p> diff --git a/content/analysis_11c-pk11195.html b/content/analysis_11c-pk11195.html index a92e0bf7a80398afe2108b610072da2118d45f24..cb3e343b46fd7e856227d188257ba26e73f7c203 100644 --- a/content/analysis_11c-pk11195.html +++ b/content/analysis_11c-pk11195.html @@ -14,7 +14,7 @@ tags: <div> -<p><a href="./pic/11C-PK11195.svg"><img src="./pic/11C-PK11195.svg" alt="11C-PK11195" +<p><a href="./pic/11C-PK11195.svg"><img src="./pic/11C-PK11195.svg" alt="11C-PK11195" title="11C-PK11195" style="padding:10px 0px 0px 10px; width:150px; float:right;" /></a> </p> diff --git a/content/analysis_11c-smw139.html b/content/analysis_11c-smw139.html index c2f82906423e199eadf75ac54757546d8e742f75..828ab8d6eee2a1d8cd1f421b386d7644db33bde0 100644 --- a/content/analysis_11c-smw139.html +++ b/content/analysis_11c-smw139.html @@ -13,7 +13,7 @@ tags: <p><a href="./pic/11C-SMW139.svg"> -<img src="./pic/11C-SMW139.svg" alt="[C-11]SMW139" +<img src="./pic/11C-SMW139.svg" alt="[C-11]SMW139" title="[C-11]SMW139" style="padding:10px 0px 0px 10px; width:200px; float:right;" /> </a></p> diff --git a/content/analysis_11c-ucb-j.html b/content/analysis_11c-ucb-j.html index 62234c3d9bd7c4c592a9b7fff48ea744342a503f..aa5af36a0bac792b3eb84895e44edf4dd6d04333 100644 --- a/content/analysis_11c-ucb-j.html +++ b/content/analysis_11c-ucb-j.html @@ -13,7 +13,7 @@ tags: <p><a name="fig1"></a> <a href="./pic/(C-11)UCB-J.svg"> -<img src="./pic/(C-11)UCB-J.svg" alt="[C-11]UCB-J" +<img src="./pic/(C-11)UCB-J.svg" alt="[C-11]UCB-J" title="[C-11]UCB-J" style="padding:10px 0px 0px 10px; width:180px; float:right;" /> </a></p> diff --git a/content/analysis_18f-ef5.html b/content/analysis_18f-ef5.html index f85bf03dd1a4b610826c4769f1f3ce92caa5c213..f99e1b91f2b53906081dd49d022abf2d225426d6 100644 --- a/content/analysis_18f-ef5.html +++ b/content/analysis_18f-ef5.html @@ -7,7 +7,7 @@ tags: - Hypoxia --- -<p><a href="./pic/18F-EF5.svg"><img src="./pic/18F-EF5.svg" alt="F-18 labelled EF5" +<p><a href="./pic/18F-EF5.svg"><img src="./pic/18F-EF5.svg" alt="F-18 labelled EF5" title="F-18 labelled EF5" style="padding:10px 0px 0px 10px; width:180px; float:right;" /></a></p> <h1>[<sup>18</sup>F]EF5 PET</h1> diff --git a/content/analysis_18f-fbpa.html b/content/analysis_18f-fbpa.html index 62bf7970b51bc37271e3f0645baee03210252f5c..d3bd9f6ecb1651a87961b045ce72917d06124547 100644 --- a/content/analysis_18f-fbpa.html +++ b/content/analysis_18f-fbpa.html @@ -33,9 +33,9 @@ The effective dose from [<sup>18</sup>F]FBPA PET study is similar than that of <figure style="border: 1px solid #000;"> <a href="./pic/L-BPA.svg"> - <img style="width:250px; margin: 0.5em;" src="./pic/L-BPA.svg" alt="L-BPA"></a> + <img style="width:250px; margin: 0.5em;" src="./pic/L-BPA.svg" alt="L-BPA" title="L-BPA"></a> <a href="./pic/(F-18)FBPA.svg"> - <img style="width:250px; margin: 0.5em;" src="./pic/(F-18)FBPA.svg" alt="FBPA"></a> + <img style="width:250px; margin: 0.5em;" src="./pic/(F-18)FBPA.svg" alt="FBPA" title="FBPA"></a> <figcaption style="margin: 0.5em;"><strong>L-BPA and [<sup>18</sup>F]FBPA</strong> </figcaption> </figure> @@ -228,10 +228,6 @@ the <sup>10</sup>B in organs (normal tissues) by simply multiplying the relative [<sup>18</sup>F]FBPA per g tissue by the therapeutic dose (g) of L-BPA, neglecting possible saturation effects from the much higher mass of the L-BPA dose.</p> -<-- - ---> - <br> <h2>See also:</h2> diff --git a/content/analysis_18f-fda.html b/content/analysis_18f-fda.html index d40d56b68ef13bee8328f59bbffd4b6ea3002bbd..c6674982e62aa98a9ef9254ab7237a66a92cb0f2 100644 --- a/content/analysis_18f-fda.html +++ b/content/analysis_18f-fda.html @@ -17,9 +17,11 @@ tags: <figure style="border: 1px solid #000;"> <a href="./pic/norepinephrine.svg"> - <img style="width:220px; margin: 0.5em;" src="./pic/norepinephrine.svg" alt="Norepinephrine"></a> + <img style="width:220px; margin: 0.5em;" src="./pic/norepinephrine.svg" + alt="Norepinephrine" title="Norepinephrine"></a> <a href="./pic/6-18F-FDA.svg"> - <img style="width:220px; margin: 0.5em;" src="./pic/6-18F-FDA.svg" alt="6-[F-18]-FDA"></a> + <img style="width:220px; margin: 0.5em;" src="./pic/6-18F-FDA.svg" + alt="6-[F-18]-FDA" title="6-[F-18]-FDA"></a> <figcaption style="margin: 0.5em;">Norepinephrine (noradrenaline) and 6-[<sup>18</sup>F]fluorodopamine (6-[<sup>18</sup>F]FDA) </figcaption> diff --git a/content/analysis_18f-fdg.html b/content/analysis_18f-fdg.html index 8dda7f62d3a228189b4474c942873b2f4decd97d..5b68d5e272eba16c48379766a5ce9c22e7b46d26 100644 --- a/content/analysis_18f-fdg.html +++ b/content/analysis_18f-fdg.html @@ -19,8 +19,8 @@ tags: <h1>Quantification of metabolic rate of glucose uptake with [<sup>18</sup>F]FDG</h1> <p><a href="./pic/(F-18)fdg.svg"> -<img src="./pic/(F-18)fdg.svg" alt="2-[F-18]fluoro-2-deoxy-D-glucose" - style="padding:10px 0px 0px 10px; width:200px; float:right;" /> +<img src="./pic/(F-18)fdg.svg" style="padding:10px 0px 0px 10px; width:200px; float:right;" + alt="2-[F-18]fluoro-2-deoxy-D-glucose" title="2-[F-18]fluoro-2-deoxy-D-glucose" /> </a></p> <p>[<sup>18</sup>F]2-fluoro-2-deoxy-D-glucose ([<sup>18</sup>F]FDG) is a <a href="./glucose.html" diff --git a/content/analysis_18f-fdopa.html b/content/analysis_18f-fdopa.html index 3127535f200656c09dd7cca4a80d5c3434a22747..ef16ff25d60d74917c67f20abb099cb1931385b5 100644 --- a/content/analysis_18f-fdopa.html +++ b/content/analysis_18f-fdopa.html @@ -32,9 +32,9 @@ and [<sup>18</sup>F]FPDOPA <figure style="border: 1px solid #000;"> <a href="./pic/L-DOPA.svg"> - <img style="width:250px; margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA"></a> + <img style="width:250px; margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA" title="L-DOPA"></a> <a href="./pic/6-(F-18)FDOPA.svg"> - <img style="width:250px; margin: 0.5em;" src="./pic/6-(F-18)FDOPA.svg" alt="FDOPA"></a> + <img style="width:250px; margin: 0.5em;" src="./pic/6-(F-18)FDOPA.svg" alt="FDOPA" title="FDOPA"></a> <figcaption style="margin: 0.5em;"><strong>L-DOPA and 6-[<sup>18</sup>F]FDOPA</strong> </figcaption> </figure> diff --git a/content/analysis_18f-fgln.html b/content/analysis_18f-fgln.html index f7004b9cc0ae258bb1199878cf68ea44d969cf0f..af2fb75f97627e1c27c9f9f58030d153e2b6d856 100644 --- a/content/analysis_18f-fgln.html +++ b/content/analysis_18f-fgln.html @@ -12,7 +12,7 @@ tags: <h1>(2<em>S</em>,4<em>R</em>)-4-[<sup>18</sup>F]fluoroglutamine</h1> <div><a href="./pic/2S4R-4-18F-FGln.png"><img src="./pic/2S4R-4-18F-FGln.png" - alt="(2S,4R)-4-[18F]fluoroglutamine" + alt="(2S,4R)-4-[18F]fluoroglutamine" title="(2S,4R)-4-[18F]fluoroglutamine" style="padding:10px 0px 0px 10px; width:200px; float:right;" /></a></div> <p><a href="./glutamine.html">L-Glutamine</a> (Gln) has many important functions in diff --git a/content/analysis_18f-fpa.html b/content/analysis_18f-fpa.html index ccf4d6e1219649c65f79d45a4ed629bcecb22002..dad0b116f38256c1e743685e64a1dcfda5ebf1b9 100644 --- a/content/analysis_18f-fpa.html +++ b/content/analysis_18f-fpa.html @@ -13,7 +13,8 @@ tags: <p><a href="./pic/2-18F-fluoropropionate.svg"><img src="./pic/2-18F-fluoropropionate.svg" - alt="18F-labelled propionate" style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a> + alt="18F-labelled propionate" title="18F-labelled propionate" + style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a> </p> <p>2-[<sup>18</sup>F]fluoropropionate (2-[<sup>18</sup>F]fluoropropionic acid, [<sup>18</sup>F]FPA) diff --git a/content/analysis_18f-fpatpp.html b/content/analysis_18f-fpatpp.html index 843f0a57c54b02fe16ace9fdcd1cfc97e7605e63..312ec78557bde647ffbedf169acd8088f593b7d8 100644 --- a/content/analysis_18f-fpatpp.html +++ b/content/analysis_18f-fpatpp.html @@ -8,7 +8,7 @@ tags: - Cannabinoids --- -<div><a href="./pic/18F-FPATPP.png"><img src="./pic/18F-FPATPP.png" alt="[18F]FPATPP" +<div><a href="./pic/18F-FPATPP.png"><img src="./pic/18F-FPATPP.png" alt="[18F]FPATPP" title="[18F]FPATPP" style="padding:10px 0px 0px 10px; width:260px; float:right;" /></a></div> <h1>[<sup>18</sup>F]FPATPP PET</h1> diff --git a/content/analysis_18f-fpia.html b/content/analysis_18f-fpia.html index ee9c7d435b163f80c6c33a097d6574b5b347cd13..51fe36726fed767f62c4e17c56e0c18a82fdd820 100644 --- a/content/analysis_18f-fpia.html +++ b/content/analysis_18f-fpia.html @@ -11,7 +11,8 @@ tags: <h1>[<sup>18</sup>F]FPIA PET</h1> <p><a href="./pic/18F-FPIA.svg"><img src="./pic/18F-FPIA.svg" - alt="18F-labelled pivalate" style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a> + alt="18F-labelled pivalate" title="18F-labelled pivalate" + style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a> </p> <p>[<sup>18</sup>F]Fluoro-pivalic acid ([<sup>18</sup>F]FPIA) is based on a non-natural diff --git a/content/analysis_18f-mfbg.html b/content/analysis_18f-mfbg.html index 55a8f3a0ee98844821ee8b61056338c45cbfe43c..4c7c6ced20a43aa1a8c0e781bfadc8e15fef9e65 100644 --- a/content/analysis_18f-mfbg.html +++ b/content/analysis_18f-mfbg.html @@ -33,11 +33,14 @@ is safer, allows same-day imaging, and better image quality than what is possibl <figure style="border: 1px solid #000;"> <a href="./pic/norepinephrine.svg"> - <img style="width:160px; margin: 0.5em;" src="./pic/norepinephrine.svg" alt="Noradrenaline"></a> + <img style="width:160px; margin: 0.5em;" src="./pic/norepinephrine.svg" + alt="Noradrenaline" title="Noradrenaline"></a> <a href="./pic/123I-MIBG.svg"> - <img style="width:200px; margin: 0.5em;" src="./pic/123I-MIBG.svg" alt="[I-123]MIBG"></a> + <img style="width:200px; margin: 0.5em;" src="./pic/123I-MIBG.svg" + alt="[I-123]MIBG" title="[I-123]MIBG"></a> <a href="./pic/18F-MFBG.svg"> - <img style="width:200px; margin: 0.5em;" src="./pic/18F-MFBG.svg" alt="[F-18]MFBG"></a> + <img style="width:200px; margin: 0.5em;" src="./pic/18F-MFBG.svg" + alt="[F-18]MFBG" title="[F-18]MFBG"></a> <figcaption style="margin: 0.5em;">Noradrenaline, [<sup>123</sup>I]MIBG, and [<sup>18</sup>F]MFBG </figcaption> </figure> diff --git a/content/analysis_18f-psma-1007.html b/content/analysis_18f-psma-1007.html index b5916a48b9e3df2335639b51da94a1268b895c36..34352c830e8e9c1168435531cea1c0a6f793663e 100644 --- a/content/analysis_18f-psma-1007.html +++ b/content/analysis_18f-psma-1007.html @@ -9,7 +9,8 @@ tags: --- -<div><a href="./pic/18F-PSMA-1007.svg"><img src="./pic/18F-PSMA-1007.svg" alt="[18F]PSMA-1007" +<div><a href="./pic/18F-PSMA-1007.svg"><img src="./pic/18F-PSMA-1007.svg" + alt="[18F]PSMA-1007" title="[18F]PSMA-1007" style="padding:10px 0px 0px 10px; width:300px; float:right;" /></a></div> @@ -117,7 +118,6 @@ was 0.05±0.02 min<sup>-1</sup> in prostate cancer lesions; 0.09±0.08, 0.15±0.08, and 0.04±0.02 in bone metastases; median <em>k<sub>3</sub></em> was 35-fold higher than <em>k<sub>4</sub></em> in prostate cancer lesions (<a href="https://doi.org/10.1007/s00259-019-04569-0">Sachpekidis et al., 2020</a>). - </p> <h3>Mass effect</h3> diff --git a/content/bnct.html b/content/bnct.html index 67cfaf47e608f86aab0284bbddc4398873830390..6198769f0f7297bbf4445cacc8bcadd421b182a6 100644 --- a/content/bnct.html +++ b/content/bnct.html @@ -47,7 +47,7 @@ this highly useful technique. Accelerator-based neutron sources are being develo <div> <a href="./pic/L-BPA.svg"> -<img src="./pic/L-BPA.svg" alt="L-BPA" +<img src="./pic/L-BPA.svg" alt="L-BPA" title="L-BPA" style="padding:8px 0px 0px 8px; width:180px; float:right;" /></a> <p>Numerous boron carriers have been developed and studied, and two, diff --git a/content/citrate.html b/content/citrate.html index 840bd2398c83c1cf39c4a4db53f8cbb1efcf8b50..8c8040a7f61c813954a2a72b96b78ccc4836be3a 100644 --- a/content/citrate.html +++ b/content/citrate.html @@ -10,7 +10,7 @@ tags: <p> <a href="./pic/citrate.svg"> -<img src="./pic/citrate.svg" alt="citrate ion" +<img src="./pic/citrate.svg" alt="citrate ion" title="citrate ion" style="padding:10px 0px 0px 10px; width:180px; float:right;" /> </a> </p> diff --git a/content/glucose.html b/content/glucose.html index 29615b219ef682bbc192d34419e1427296051e96..777922fb1bcbf07dd9b42878c7517057a14a883e 100644 --- a/content/glucose.html +++ b/content/glucose.html @@ -16,7 +16,7 @@ tags: <p> <a href="./pic/D-glucose.svg"> -<img src="./pic/D-glucose.svg" alt="D-Glucose" +<img src="./pic/D-glucose.svg" alt="D-Glucose" title="D-Glucose" style="padding:10px 0px 0px 10px; width:200px; float:right;" /> </a> </p> diff --git a/content/ketones.html b/content/ketones.html index 596fbf05dad10cd49488499782c76e3854071fad..5c717ef0572bc95ea49276b7ddc8a23d53418ef0 100644 --- a/content/ketones.html +++ b/content/ketones.html @@ -12,21 +12,21 @@ tags: <p>Ketone bodies include acetoacetate (AcAc), D-β-hydroxybutyrate (β-HB, BHB), and acetone. L-β-hydroxybutyrate is not used in energy metabolism but excreted in the urine.<p> -<table class="borderless" style="width: 95%;"> +<table class="borderless" id="borderlesstable" style="width: 95%;"> <tr> <td><figure style="border: 0px;"> <a href="./pic/acetone.svg"> - <img style="margin: 0.5em;" src="./pic/acetone.svg" alt="Acetone"></a> + <img style="margin: 0.5em;" src="./pic/acetone.svg" alt="Acetone" title="Acetone"></a> <figcaption style="margin: 0.5em;">Acetone</figcaption> </figure></td> <td><figure style="border: 0px;"> <a href="./pic/acac.svg"> - <img style="margin: 0.5em;" src="./pic/acac.svg" alt="Acetoacetate"></a> + <img style="margin: 0.5em;" src="./pic/acac.svg" alt="Acetoacetate" title="Acetoacetate"></a> <figcaption style="margin: 0.5em;">Acetoacetate (AcAc)</figcaption> </figure></td> <td><figure style="border: 0px;"> <a href="./pic/bhb.svg"> - <img style="margin: 0.5em;" src="./pic/bhb.svg" alt="beta-hydroxybutyrate"></a> + <img style="margin: 0.5em;" src="./pic/bhb.svg" alt="beta-hydroxybutyrate" title="beta-hydroxybutyrate"></a> <figcaption style="margin: 0.5em;">β-hydroxybutyrate (β-HB)</figcaption> </figure></td> </tr> @@ -84,23 +84,24 @@ and β-hydroxybutyrate with <sup>11</sup>C and <sup>18</sup>F, giving (3<em>S</em>)-4-[<sup>18</sup>F]fluoro-3-hydroxybutyric acid ([<sup>18</sup>F]FBHB). Ketones have also been labelled with <sup>13</sup>C for NMR studies.</p> -<table class="borderless" style="width: 95%;"> +<table class="borderless" id="borderlesstable" style="width: 95%;"> <tr> <td><figure style="border: 0px;"> <a href="./pic/1-11C-acetoacetate.svg"> - <img style="margin: 0.5em;" src="./pic/1-11C-acetoacetate.svg" alt="[1-11C]acetoacetate"></a> + <img style="margin: 0.5em;" src="./pic/1-11C-acetoacetate.svg" + alt="[1-11C]acetoacetate" title="[1-11C]acetoacetate"></a> <figcaption style="margin: 0.5em;">[<sup>11</sup>C]AcAc</figcaption> </figure></td> <td><figure style="border: 0px;"> <a href="./pic/beta-1-11C-hydroxybutyrate.svg"> <img style="margin: 0.5em;" src="./pic/beta-1-11C-hydroxybutyrate.svg" - alt="beta-[1-11C]-hydroxybutyrate"></a> + alt="beta-[1-11C]-hydroxybutyrate" title="beta-[1-11C]-hydroxybutyrate"></a> <figcaption style="margin: 0.5em;">[<sup>11</sup>C]β-HB</figcaption> </figure></td> <td><figure style="border: 0px;"> <a href="./pic/4-18F-3-hydroxybutyrate.svg"> <img style="margin: 0.5em;" src="./pic/4-18F-3-hydroxybutyrate.svg" - alt="4-[18F]-3-hydroxybutyrate"></a> + alt="4-[18F]-3-hydroxybutyrate" title="4-[18F]-3-hydroxybutyrate"></a> <figcaption style="margin: 0.5em;">[<sup>18</sup>F]FBHB</figcaption> </figure></td> </tr> diff --git a/content/lactate.html b/content/lactate.html index 16d76ff81ea22038af1358b14c0be175158b5a95..e7e6ec09ead2f9c0bad9e0300c87a6d13e6c4590 100644 --- a/content/lactate.html +++ b/content/lactate.html @@ -47,7 +47,7 @@ mediate metabolic signals through the nervous tissue present at physiological pH.</p> <p><a href="./pic/lactate-pyruvate.svg"><img src="./pic/lactate-pyruvate.svg" - alt="lactate-pyruvate conversion by LDH" + alt="lactate-pyruvate conversion by LDH" title="lactate-pyruvate conversion by LDH" style="padding:6px 0px 0px 6px; width:320px; float:right;" /></a> </p> @@ -61,7 +61,7 @@ L-lactate can be concerted back to glucose via gluconeogenesis. Kidneys maintain pyruvate/lactate ratio in circulation by converting lactate into pyruvate.</p> <p><a href="./pic/pyruvate-acetylCoA.svg"><img src="./pic/pyruvate-acetylCoA.svg" - alt="pyruvate to acetyl-CoA conversion by PDH" + alt="pyruvate to acetyl-CoA conversion by PDH" title="pyruvate to acetyl-CoA conversion by PDH" style="padding:6px 0px 0px 6px; width:350px; float:right;" /></a> </p> @@ -238,14 +238,17 @@ the TCA cycle.</p> <div class="images"> <a href="./pic/L-1-11C-lactate.svg"> -<img src="./pic/L-1-11C-lactate.svg" alt="[C-11]Lactate, labeled into C-1 position" - style="padding:0px 20px 0px 0px;" /></a> +<img src="./pic/L-1-11C-lactate.svg" style="padding:0px 20px 0px 0px;" + alt="[C-11]Lactate, labeled into C-1 position" + title="[C-11]Lactate, labeled into C-1 position" /></a> <a href="./pic/L-3-11C-lactate.svg"> -<img src="./pic/L-3-11C-lactate.svg" alt="[C-11]Lactate, labeled into C-3 position" - style="padding:0px 20px 0px 0px;" /></a> +<img src="./pic/L-3-11C-lactate.svg" style="padding:0px 20px 0px 0px;" + alt="[C-11]Lactate, labeled into C-3 position" + title="[C-11]Lactate, labeled into C-3 position" /></a> <a href="./pic/18F-S-FL.svg"> -<img src="./pic/18F-S-FL.svg" alt="[F-18]Lactate, labeled into C-3 position" - style="padding:0px 20px 0px 0px;" /></a> +<img src="./pic/18F-S-FL.svg" style="padding:0px 20px 0px 0px;" + alt="[F-18]Lactate, labeled into C-3 position" + title="[F-18]Lactate, labeled into C-3 position" /></a> <p><strong>Figure 1.</strong> L-1-[<sup>11</sup>C]lactate and L-3-[<sup>11</sup>C]lactate, labelled into C-1 and C-3 position, respectively; [<sup>18</sup>F]<em>S</em>-fluorolactate, labelled into C-3 position.</p> @@ -345,8 +348,7 @@ cells <em>in vitro</em> and tumours <em>in vivo</em> (<a href="https://doi.org/10.18632/oncotarget.14705">Van Hée et al., 2017</a>). Low levels of radioactivity in bone after 1 h of <sup>18</sup>F]-<em>S</em>-FL administration indicates a low level of defluorination of the radiotracer -(<a href="https://doi.org/10.3390/cancers12061703">Braga et al., 2020</a>). -</p> +(<a href="https://doi.org/10.3390/cancers12061703">Braga et al., 2020</a>).</p> <br> diff --git a/content/pyruvate.html b/content/pyruvate.html index 08d87ab29e46e955392a72c0dbd53da11d25ad5a..d37ee1662d6a7a2c6ae04b9f947ee0b473483ce6 100644 --- a/content/pyruvate.html +++ b/content/pyruvate.html @@ -28,7 +28,7 @@ L-lactate dehydrogenase (LDH).</p> <p><a href="./pic/pyruvate-acetylCoA.svg"><img src="./pic/pyruvate-acetylCoA.svg" - alt="pyruvate to acetyl-CoA conversion by PDH" + alt="pyruvate to acetyl-CoA conversion by PDH" title="pyruvate to acetyl-CoA conversion by PDH" style="padding:6px 0px 0px 6px; width:350px; float:right;" /></a> </p> diff --git a/content/scfa.html b/content/scfa.html index 88e1c21bc10464bfc22066dbe2278381ba3b18bd..343fd888590e2efc2c4c67569f2230ab20b545d0 100644 --- a/content/scfa.html +++ b/content/scfa.html @@ -1,7 +1,7 @@ --- title: SCFAs author: Vesa Oikonen -updated_at: 2025-06-04 +updated_at: 2025-06-05 created_at: 2025-06-02 tags: - Fatty acids @@ -29,14 +29,14 @@ Zhang et al., <a href="https://doi.org/10.1007/s11307-019-01346-1">2019</a> and <a href="https://doi.org/10.1007/s11307-021-01608-x">2021</a>).</p> <figure style="border: 1px solid #000;"> - <img style="margin: 0.5em;" src="./pic/scfa_acetate.svg" alt="Acetate (ethanoate)"> - <img style="margin: 0.5em;" src="./pic/scfa_propionate.svg" alt="Propionate (propanoate)"> - <img style="margin: 0.5em;" src="./pic/scfa_butyrate.svg" alt="Butyrate (butanoate)"> - <img style="margin: 0.5em;" src="./pic/scfa_valerate.svg" alt="Valerate (pentanoate)"> - <img style="margin: 0.5em;" src="./pic/scfa_isobutyrate.svg" alt="Isobutyrate (2-methylpropanoate)"> - <img style="margin: 0.5em;" src="./pic/scfa_2-methylbutyrate.svg" alt="2-Methylbutyrate (2-methylbutanoate)"> - <img style="margin: 0.5em;" src="./pic/scfa_isovalerate.svg" alt="Isovalerate (3-methylbutanoate)"> - <img style="margin: 0.5em;" src="./pic/scfa_pivalate.svg" alt="Pivalate (trimethylacetate)"> + <img style="margin: 0.5em;" src="./pic/scfa_acetate.svg" alt="Acetate (ethanoate)" title="Acetate (ethanoate)"> + <img style="margin: 0.5em;" src="./pic/scfa_propionate.svg" alt="Propionate (propanoate)" title="Propionate (propanoate)"> + <img style="margin: 0.5em;" src="./pic/scfa_butyrate.svg" alt="Butyrate (butanoate)" title="Butyrate (butanoate)"> + <img style="margin: 0.5em;" src="./pic/scfa_valerate.svg" alt="Valerate (pentanoate)" title="Valerate (pentanoate)"> + <img style="margin: 0.5em;" src="./pic/scfa_isobutyrate.svg" alt="Isobutyrate (2-methylpropanoate)" title="Isobutyrate (2-methylpropanoate)"> + <img style="margin: 0.5em;" src="./pic/scfa_2-methylbutyrate.svg" alt="2-Methylbutyrate (2-methylbutanoate)" title="2-Methylbutyrate (2-methylbutanoate)"> + <img style="margin: 0.5em;" src="./pic/scfa_isovalerate.svg" alt="Isovalerate (3-methylbutanoate)" title="Isovalerate (3-methylbutanoate)"> + <img style="margin: 0.5em;" src="./pic/scfa_pivalate.svg" alt="Pivalate (trimethylacetate)" title="Pivalate (trimethylacetate)"> </figure> <p>SCFAs include also a non-natural substrate pivalate (trimethylacetate), which cannot be oxidized diff --git a/content/stylesheets/style.css b/content/stylesheets/style.css index 5d145c216e9542295f4fe743f0e6f533641a00aa..49c74f066c8d45a244c59cc5c4178d762be857a1 100644 --- a/content/stylesheets/style.css +++ b/content/stylesheets/style.css @@ -262,6 +262,10 @@ table.borderless th, tr, td { border-collapse: collapse; border: 0px; } +#borderlesstable { + border-collapse: collapse; + border: 0; +} table.mask, tr, td { border: 1px solid black; diff --git a/content/target_adenosine.html b/content/target_adenosine.html index 7eaeafa5236cd842325b91ea39a7c48e43c250c7..2a94b24206ecf07e7fd1ef4cca29fcb92c9acc8b 100644 --- a/content/target_adenosine.html +++ b/content/target_adenosine.html @@ -19,7 +19,7 @@ tags: <div> <a href="./pic/adenosine.svg"> -<img src="./pic/adenosine.svg" alt="Adenosine" +<img src="./pic/adenosine.svg" alt="Adenosine" title="Adenosine" style="padding:10px 0px 0px 10px; width:160px; float:right;" /> </a> @@ -103,8 +103,7 @@ radiopharmaceuticals for A<sub>1</sub>R and A<sub>2A</sub>R are routinely used i Agonists, including endogenous agonist adenosine, lead to the activation of all AR subtypes, and subsequent regulation by desensitization and trafficking (<a href="https://doi.org/10.1016/j.bbamem.2010.06.007">Mundell and Kelly, 2011</a>). -In addition to AR agonists and antagonists, also allosteric modulators have been introduced. -</p> +In addition to AR agonists and antagonists, also allosteric modulators have been introduced.</p> <h3><a name="a1r">A<sub>1</sub>R</a></h3> diff --git a/content/target_adrenergic_system.html b/content/target_adrenergic_system.html index 1d0345dd321bc4bc83b079b3fcf1a428b610c003..3e6cdf484541f9b25b834464f3f7fc11807f81e6 100644 --- a/content/target_adrenergic_system.html +++ b/content/target_adrenergic_system.html @@ -25,10 +25,10 @@ as neurohormones from <a href="./organ_adrenal_gland.html">adrenal medulla</a>. <div class="images"> <a href="./pic/epinephrine.svg"> -<img src="./pic/epinephrine.svg" alt="Epinephrine/Adrenaline" +<img src="./pic/epinephrine.svg" alt="Epinephrine/Adrenaline" title="Epinephrine/Adrenaline" style="padding:0px 20px 0px 0px;" /></a> <a href="./pic/norepinephrine.svg"> -<img src="./pic/norepinephrine.svg" alt="Norepinephrine/Noradrenaline" +<img src="./pic/norepinephrine.svg" alt="Norepinephrine/Noradrenaline" title="Norepinephrine/Noradrenaline" style="padding:0px 20px 0px 0px;" /></a> <p>Adrenaline (epinephrine) and noradrenaline (norepinephrine).</p> </div> @@ -69,24 +69,24 @@ Noradrenaline is metabolized by MAO-A and MAO-B, and COMT.</p> <tr> <td><figure style="border: 0px;"> <a href="./pic/L-phenylalanine.svg"> - <img style="margin: 0.5em;" src="./pic/L-phenylalanine.svg" alt="L-Phenylalanine"></a> + <img style="margin: 0.5em;" src="./pic/L-phenylalanine.svg" alt="L-Phenylalanine" title="L-Phenylalanine"></a> <figcaption style="margin: 0.5em;">L-Phenylalanine</figcaption> </figure></td> <td><figure style="border: 0px;"> <a href="./pic/L-tyrosine.svg"> - <img style="margin: 0.5em;" src="./pic/L-tyrosine.svg" alt="L-Tyrosine"></a> + <img style="margin: 0.5em;" src="./pic/L-tyrosine.svg" alt="L-Tyrosine" title="L-Tyrosine"></a> <figcaption style="margin: 0.5em;">L-Tyrosine</figcaption> </figure></td> </tr> <tr> <td><figure style="border: 0px;"> <a href="./pic/L-DOPA.svg"> - <img style="margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA"></a> + <img style="margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA" title="L-DOPA"></a> <figcaption style="margin: 0.5em;">L-DOPA</figcaption> </figure></td> <td><figure style="border: 0px;"> <a href="./pic/dopamine.svg"> - <img style="margin: 0.5em;" src="./pic/dopamine.svg" alt="Dopamine"></a> + <img style="margin: 0.5em;" src="./pic/dopamine.svg" alt="Dopamine" title="Dopamine"></a> <figcaption style="margin: 0.5em;">Dopamine</figcaption> </figure></td> </tr> diff --git a/content/target_ar.html b/content/target_ar.html index 4f661b01411e2d289db20d24d574406c10b4f92d..e0fea0ae0adec973a6481a43cb16160c0ca861ac 100644 --- a/content/target_ar.html +++ b/content/target_ar.html @@ -13,7 +13,7 @@ tags: <figure style="float:right;"> <a href="./pic/testosterone.svg"> - <img src="./pic/testosterone.svg" alt="Testosterone" style="width:140px;" /></a> + <img src="./pic/testosterone.svg" alt="Testosterone" title="Testosterone" style="width:140px;" /></a> <figcaption style="margin: 0.5em; font-size: 75%;">Testosterone</figcaption> </figure> @@ -45,7 +45,7 @@ SHBG binding also helps in hormone transport into target cells through membrane (DHEA), further to androstenedione, and to testosterone (<a href="https://doi.org/10.1016/j.mednuc.2015.02.005">Lefebvre-Lacœuille et al., 2015</a>). Testosterone is produced primarily in testicular Leydig cells in men, while in women precursors are -biosynthesised in the <a href="./organ_adrenal_gland.html">adrenal cortex</a> and +biosynthesized in the <a href="./organ_adrenal_gland.html">adrenal cortex</a> and <a href="./organ_ovary.html">ovaries</a> and converted into testosterone in peripheral tissues. </p> @@ -86,7 +86,7 @@ AR radioligands, such as [<sup>18</sup>F]FDHT <figure style="float:right;"> <a href="./pic/18F-FDHT.svg"> - <img src="./pic/18F-FDHT.svg" alt="[F-18]FDHT" style="width:170px;" /></a> + <img src="./pic/18F-FDHT.svg" alt="[F-18]FDHT" title="[F-18]FDHT" style="width:170px;" /></a> </figure> <p>16β-[<sup>18</sup>F]fluoro-5α-dihydrotestosterone ([<sup>18</sup>F]FDHT) diff --git a/content/target_dopamine.html b/content/target_dopamine.html index 6c113b80cd2c1e832a2df3cc45dbdf7d88ea6c31..a72b9633f61033cae78862a1de27fb49d7f54a0f 100644 --- a/content/target_dopamine.html +++ b/content/target_dopamine.html @@ -90,9 +90,9 @@ Dopamine is packaged into synaptic vesicles by vesicular monoamine transporter 2 <figure style="border: 1px solid #000;"> <a href="./pic/dopamine.svg"> - <img style="width:200px; margin: 0.5em;" src="./pic/dopamine.svg" alt="Dopamine"></a> + <img style="width:200px; margin: 0.5em;" src="./pic/dopamine.svg" alt="Dopamine" title="Dopamine"></a> <a href="./pic/L-DOPA.svg"> - <img style="width:250px; margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA"></a> + <img style="width:250px; margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA" title="L-DOPA"></a> <figcaption style="margin: 0.5em;">Dopamine and L-DOPA</figcaption> </figure> diff --git a/content/target_sv2.html b/content/target_sv2.html index 8acb4dcd140a06d972c1a1e2d9f6faac44f79a73..9c224dd52242d146a3aea83368b0d3cc3f9f2ecb 100644 --- a/content/target_sv2.html +++ b/content/target_sv2.html @@ -92,12 +92,12 @@ levetiracetam. SV2A modulates epileptogenesis via GABAergic, but not glutamaterg <tr> <td><figure style="border: 0px;"> <a href="./pic/levetiracetam.svg"> - <img style="margin: 0.5em;" src="./pic/levetiracetam.svg" alt="Levetiracetam"></a> + <img style="margin: 0.5em;" src="./pic/levetiracetam.svg" alt="Levetiracetam" title="Levetiracetam"></a> <figcaption style="margin: 0.5em;">Levetiracetam</figcaption> </figure></td> <td><figure style="border: 0px;"> <a href="./pic/brivaracetam.svg"> - <img style="margin: 0.5em;" src="./pic/brivaracetam.svg" alt="Brivaracetam"></a> + <img style="margin: 0.5em;" src="./pic/brivaracetam.svg" alt="Brivaracetam" title="Brivaracetam"></a> <figcaption style="margin: 0.5em;">Brivaracetam</figcaption> </figure></td> </tr> @@ -160,24 +160,24 @@ The specific binding of [<sup>18</sup>F]UCB-H is relatively low, hampering quant <tr> <td><figure style="border: 0px;"> <a href="./pic/UCB-J.svg"> - <img style="margin: 0.5em;" src="./pic/UCB-J.svg" alt="UCB-J"></a> + <img style="margin: 0.5em;" src="./pic/UCB-J.svg" alt="UCB-J" title="UCB-J"></a> <figcaption style="margin: 0.5em;">UCB-J</figcaption> </figure></td> <td><figure style="border: 0px;"> <a href="./pic/UCB-H.svg"> - <img style="margin: 0.5em;" src="./pic/UCB-H.svg" alt="UCB-H"></a> + <img style="margin: 0.5em;" src="./pic/UCB-H.svg" alt="UCB-H" title="UCB-H"></a> <figcaption style="margin: 0.5em;">UCB-H</figcaption> </figure></td> </tr> <tr> <td><figure style="border: 0px;"> <a href="./pic/SynVesT-1.svg"> - <img style="margin: 0.5em;" src="./pic/SynVesT-1.svg" alt="SynVesT-1"></a> + <img style="margin: 0.5em;" src="./pic/SynVesT-1.svg" alt="SynVesT-1" title="SynVesT-1"></a> <figcaption style="margin: 0.5em;">SynVesT-1, MNI-1126, SDM-8</figcaption> </figure></td> <td><figure style="border: 0px;"> <a href="./pic/SynVesT-2.svg"> - <img style="margin: 0.5em;" src="./pic/SynVesT-2.svg" alt="SynVesT-2"></a> + <img style="margin: 0.5em;" src="./pic/SynVesT-2.svg" alt="SynVesT-2" title="SynVesT-2"></a> <figcaption style="margin: 0.5em;">SynVesT-2, SDM-2</figcaption> </figure></td> </tr> @@ -190,11 +190,11 @@ radioligands (<a href="https://doi.org/10.1007/s00259-021-05597-5">Zheng et al., <table class="borderless" style="width: 95%;"> <tr> <td><figure style="border: 0px;"> - <a href="./pic/UCB-A.svg"><img style="margin: 0.5em;" src="./pic/UCB-A.svg" alt="UCB-A"></a> + <a href="./pic/UCB-A.svg"><img style="margin: 0.5em;" src="./pic/UCB-A.svg" alt="UCB-A" title="UCB-A"></a> <figcaption style="margin: 0.5em;">UCB-A</figcaption> </figure></td> <td><figure style="border: 0px;"> - <a href="./pic/SDM-16.svg"><img style="margin: 0.5em;" src="./pic/SDM-16.svg" alt="SDM-16"></a> + <a href="./pic/SDM-16.svg"><img style="margin: 0.5em;" src="./pic/SDM-16.svg" alt="SDM-16" title="SDM-16"></a> <figcaption style="margin: 0.5em;">SDM-16</figcaption> </figure></td> </tr>